Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte has entered a definitive agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion in upfront cash. The deal adds VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio. VGA039 is a first-in-class subcutaneous therapy with Breakthrough Therapy designation. Star Therapeutics is eligible for up to $750 million in additional sales milestones, bringing total potential consideration to $2.0 billion.
Key figures
- Deal Value Usd
- 1250000000
- Expected rd charge
- $1.25 billion
- Milestone payments
- $750 million
- Total potential consideration
- $2.0 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.